Jay Hendler, MD
Pulmonary Disease · Gastonia, NCNPI 1467412171
Payments from drug & device makers
Across 207 payments — averaging $83.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$8K
- GSK$3K
- Grifols USA, LLC$2K
- Medtronic$1K
- Intuitive Surgical$595
- AstraZeneca$424
- plus $2K from 33 others
What the payments were for
- Speaking & faculty fees$11,50867%
- Travel & lodging$1,85111%
- Food & beverage$3,92723%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 25 | $7,754 |
| GSK | 35 | $2,934 |
| Grifols USA, LLC | 21 | $2,214 |
| Medtronic | 13 | $1,384 |
| Intuitive Surgical | 6 | $595 |
| AstraZeneca | 20 | $424 |
| Insmed, Inc. | 12 | $261 |
| Actelion Pharmaceuticals US, Inc. | 6 | $161 |
| Verona Pharma, Inc. | 2 | $126 |
| United Therapeutics Corporation | 5 | $123 |
| Pulmonx Corporation | 2 | $120 |
| Sanofi | 4 | $103 |
| Pfizer | 5 | $103 |
| Amgen | 5 | $93 |
| Merck | 4 | $90 |
| Philips North America LLC | 4 | $84 |
| Electromed, Inc. | 3 | $56 |
| Inspire Medical Systems, Inc. | 3 | $55 |
| Regeneron Healthcare Solutions, Inc. | 2 | $52 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $50 |
| Mylan Specialty L.p. | 3 | $45 |
| Mallinckrodt Enterprises LLC | 2 | $42 |
| Shire North American Group Inc | 2 | $39 |
| Tactile Systems Technology Inc | 2 | $38 |
| 3b Medical, Inc. | 1 | $35 |
| CSL Behring | 1 | $34 |
| Genentech USA, Inc. | 2 | $32 |
| Baxter Healthcare | 1 | $29 |
| Novartis | 2 | $28 |
| Circassia Inc. | 2 | $27 |
| Viatris Specialty LLC | 1 | $22 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $22 |
| Harmony Biosciences LLC | 1 | $19 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| Veran Medical Technologies, Inc. | 1 | $17 |
| ANI Pharmaceuticals, Inc. | 1 | $16 |
| Advanced Respiratory, Inc | 2 | $14 |
| Fisher & Paykel Healthcare Inc | 1 | $12 |
| Sanofi Pasteur Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$2,400
- Prolastin-C$1,420
- ILLUMISITE$1,148
- Da Vinci Surgical System$534
- Prolastin-C Liquid$473
- Pulmonx Endobronchial Valve EBV$105
- Ohtuvayre$105
How this compares
$17,285 in reported general payments places this provider in the 75th percentile of 393 pulmonary disease providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 697 | $520,828 |
| Breo ElliptaFluticasone/Vilanterol | 448 | $240,425 |
| XolairOmalizumab | 26 | $131,267 |
| Dupixent SyringeDupilumab | 25 | $113,731 |
| Dupixent PenDupilumab | 18 | $65,310 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 90 | $59,918 |
| SymbicortBudesonide/Formoterol Fumarate | 96 | $28,790 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 39 | $22,194 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 477 | $11,653 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 20 | $11,642 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 37 | $9,711 |
| Incruse ElliptaUmeclidinium Bromide | 27 | $9,304 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 80 | $9,183 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 13 | $6,976 |
| XareltoRivaroxaban | 12 | $5,752 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta | $2,934 | $777,5331,185 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $424 | $88,708186 claims |
| Boehringer IngelheimStiolto Respimat, Combivent Respimat | $7,754 | $33,83659 claims |
| MerckDulera | $90 | $4,83514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 393 pulmonary disease providers in North Carolina.
Other pulmonary disease in Gastonia
- Anup BanerjeeGastonia$2.1M
- Mikell JarrattGastonia$1.7M
- Emeka EziriGastonia$252K
- Raed SuleimanGastonia$195K
- Selwyn SpangenthalCharlotte$7M
- Thomas SternHuntersville$5.2M
- Laurie SnyderDurham$3.8M
- Scott PalmerDurham$3.8M
- Michael PritchettPinehurst$2.2M
- Hubert FordChapel Hill$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.